High Triglycerides and Low HDL Cholesterol and Blood Pressure and Risk of Ischemic Heart Disease

Jørgen Jeppesen, Hans Ole Hein, Poul Suadicani, Finn Gyntelberg

**Abstract**—Treatment of high blood pressure (BP) has not produced the expected reduction in risk of ischemic heart disease (IHD). Subjects with high BP often have the metabolic syndrome X, an aggregation of abnormalities in glucose and lipid metabolism. We tested the hypothesis that the BP level would be less predictive of risk of IHD in those with high triglycerides (TG) and low HDL cholesterol (HDL-C), the characteristic dyslipidemia in the metabolic syndrome than in those without. Baseline measurements of fasting lipids, systolic BP (SBP), diastolic BP (DBP), and other risk factors were obtained in 2906 men, age 53 to 74 years, free of overt cardiovascular disease. High TG/low HDL-C was defined as TG >1.59 mmol/L and HDL-C <1.18 mmol/L. Within an 8-year period, 229 men developed IHD. In men with high TG/low HDL-C, the incidence of IHD according to SBP (<120, 120 to 140, >140 mm Hg) was 12.5%, 12.9%, and 10.0% (P = NS), respectively, and according to DBP, the incidence of IHD was (<75, 75 to 90, >90 mm Hg) 13.7%, 10.6%, and 13.7% (P = NS), respectively. The corresponding figures for other men were 5.2%, 8.0%, and 9.7% for SBP (P < 0.001), and 6.1%, 7.5%, and 9.9% for DBP (P < 0.03). In conclusion, the BP level did not predict the risk of IHD in those with high TG/low HDL-C. This finding may explain the reason lowering BP has not produced the expected reduction in IHD. (Hypertension. 2000;36:226-232.)

**Key Words:** coronary disease ■ blood pressure ■ lipids ■ lipoproteins ■ risk factors

Although high blood pressure (BP) is a strong risk factor of ischemic heart disease (IHD), lowering BP in patients with hypertension has not produced the expected reductions in morbidity and mortality from IHD. This paradox was highlighted by the results of the Hypertension Optimal Treatment (HOT) Study. In the HOT study, drug-treated hypertensive patients had the same risk of IHD during the study period whether they had a diastolic blood pressure (DBP) of 105 mm Hg or 75 mm Hg, and they basically had the same risk of IHD whether they had a systolic blood pressure (SBP) of 170 mm Hg or 120 mm Hg.

As a group, patients with high BP have the metabolic syndrome X, a cluster of multiple interrelated abnormalities in glucose and lipid metabolism that tend to increase their risk of IHD. It is believed that resistance to insulin-stimulated glucose uptake with compensatory hyperinsulinemia is the primary culprit in the metabolic syndrome X. It has been proposed that it is the presence of this cluster of risk factors for IHD in patients with hypertension that explains why interventions directed solely to the lowering of BP has had relatively little beneficial effect on risk of IHD. However, this hypothesis has not yet been tested in a prospective study.

In the Copenhagen Male Study (CMS), we found that the characteristic dyslipidemia seen in subjects with the metabolic syndrome X, that is, high plasma triglycerides (TG) and low HDL cholesterol, is an important risk factor of IHD. The present analysis was initiated to test the hypothesis that the level of BP would be less predictive of risk of IHD in those with high TG/low HDL cholesterol, the characteristic dyslipidemia in the metabolic syndrome X, than in those without.

**Methods**

**Study Population**

We have described the methods used in the CMS in greater detail elsewhere. The CMS began in 1970 as a cardiovascular study of 5249 men. From 1985 to 1986, a new baseline was established that was used for the present study. All survivors from the 1970 study were traced by means of the Danish Central Population Register. Between June 1985 and June 1986, all survivors (except 34 emigrants) from the original cohort were invited to take part in this study. Three thousand three hundred eighty-seven (75%) men agreed to participate in the study, and they gave informed consent. Their mean age was 63 years (range 53 to 74 years). Each subject was interviewed by a physician (H.O.H.) in regard to a previously completed questionnaire, and height, weight, and blood pressure measurements were performed. A venous blood sample for lipid measurements was taken after the subjects had fasted for 12 hours.

Men with a history of acute myocardial infarction (AMI), angina pectoris, stroke, or intermittent claudication were excluded from the follow-up study. Before the start of the study, hospital records were checked for all men who reported admission to a hospital because of AMI. Information on angina pectoris, stroke, and intermittent claudication was established from the questionnaire. Three hundred
TABLE 1. Clinical, Lifestyle, and Other Characteristics According to Level of SBP in Men Taking No Drugs to Lower BP

<table>
<thead>
<tr>
<th>Variables</th>
<th>&lt;120 mm Hg, n=1399</th>
<th>120–140 mm Hg, n=967</th>
<th>&gt;140 mm Hg, n=253</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipids, mmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>6.43 (1.09)</td>
<td>6.55 (1.08)</td>
<td>6.55 (1.11)</td>
<td>0.006</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>4.42 (1.03)</td>
<td>4.42 (1.05)</td>
<td>4.39 (1.06)</td>
<td>NS</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>1.37 (0.35)</td>
<td>1.37 (0.36)</td>
<td>1.38 (0.37)</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>1.38 (0.70)</td>
<td>1.62 (1.31)</td>
<td>1.65 (1.03)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Combined high TG/low HDL-C</td>
<td>15.9%</td>
<td>19.4%</td>
<td>21.2%</td>
<td>0.01</td>
</tr>
<tr>
<td>Lifestyle factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol use, beverages/wk</td>
<td>16.7 (13.4)</td>
<td>18.0 (13.7)</td>
<td>20.3 (15.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking</td>
<td>63%</td>
<td>51%</td>
<td>47%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Physical activity, &lt;4 h/wk</td>
<td>45%</td>
<td>46%</td>
<td>48%</td>
<td>NS</td>
</tr>
<tr>
<td>Clinical/paraclinical factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>24.9 (3.0)</td>
<td>25.9 (3.1)</td>
<td>26.4 (3.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>107 (9)</td>
<td>128 (6)</td>
<td>150 (9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>66 (9)</td>
<td>76 (10)</td>
<td>82 (9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>NIDDM</td>
<td>1%</td>
<td>2%</td>
<td>2%</td>
<td>NS</td>
</tr>
<tr>
<td>Other characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low social class</td>
<td>51%</td>
<td>49%</td>
<td>52%</td>
<td>NS</td>
</tr>
<tr>
<td>Age, y</td>
<td>62.1 (5.0)</td>
<td>63.0 (5.2)</td>
<td>63.6 (5.3)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Values are mean (SD) or frequencies in percent. P values of test for linearity in ANOVA or Kendall’s Tau for trend.

Combined high TG/low HDL-C, triglycerides >1.59 mmol/L and HDL cholesterol <1.18 mmol/L.

Results

Of the 2906 men eligible for the study, 347 reported taking medication to lower BP. Nearly 67% of these men used diuretics, ≈34% used diuretics only, 20% used diuretics in combination with another class of antihypertensive medication. Forty-two men (10.1%) were excluded because of cardiovascular diseases, and 139 men (4.1%) were excluded because of missing data. Thus, 2906 men were eligible for the prospective study.

Measurements

BP was measured on the right arm with the subject seated for ≥15 minutes by means of a manometer developed by the London School of Hygiene. Information on the use of BP lowering drugs was obtained from the questionnaire. In untreated men, hypertension was defined as a SBP >140 mm Hg or a DBP >90 mm Hg.

Serum concentrations of total cholesterol, TG, and HDL cholesterol were analyzed by standard methods. The concentration of LDL cholesterol was determined according to the Friedewald formula. Approximately 1.5% of the study population had a TG level >4.5 mmol/L, at which point the indirect LDL cholesterol calculation becomes unreliable. However, excluding subjects with TG >4.5 mmol/L from the study did not materially affect any of the results; thus, we kept this subgroup in our study.

An ECG was recorded while the subject was supine at rest with a 3-channel Mingograph-34 from 12 standard leads. The traces were coded according to the Minnesota code. Self-reported non–insulin-dependent diabetes mellitus (NIDDM) was accepted, provided the diagnosis had been verified by a physician. No measurements of plasma glucose or insulin were performed in the present cohort. Body mass index (BMI, kg/m²) was calculated from weight and height measurements.

Total weekly consumption of alcohol was calculated from questionnaire items on average alcohol consumption on weekdays and weekends. Intakes of beer, wine, and other alcoholic beverages were reported separately. One drink corresponded to 10 to 12 g of ethanol. The men classified themselves as never smokers, previous smokers, or current smokers. As estimated by means of serum cotinine, the validity of tobacco reporting was high.

With respect to leisure-time physical activity, the men classified themselves as either sedentary or slightly active, <4 hours per week, or physically more active on the basis of the questionnaire. According to the system of Svalastoga, the men were divided into 5 social classes, on the basis of their level of education and job profile.

End Points

In 1995, a register follow-up was performed on morbidity and mortality between 1985 to 1986 and December 31, 1993. All men who had taken part in the 1985 to 1986 examination were traced from registers. Information on hospital admissions and death certificate diagnoses within the follow-up period were obtained. We used the diagnoses from official national registers. IHD diagnoses accepted were codes 410 to 414 (International Classification of Diseases, 8th revision). Previous studies have demonstrated a high validity of Danish National registers.

Statistical Analysis

Variables of interest were expressed as mean±SD or frequencies in percent. The study population was divided into various subgroups according to (1) SBP <120, 120 to 140, >140 mm Hg; (2) DBP <75, 75 to 90, >90 mm Hg; (3) presence of high TG/low HDL cholesterol, belonging to both the highest third of TG levels (>1.59 mmol/L) and lowest third of HDL cholesterol levels (<1.18 mmol/L) in the population; and (4) taking drugs to lower BP. Differences between groups were tested by ANOVA, Student’s t test, χ² test for heterogeneity, or Kendall’s Tau B test for trend when appropriate. The simultaneous contribution of several factors to the risk of IHD was analyzed with multiple logistic regression models and the maximum likelihood ratio method. All calculations were performed with the SPSSPC+ statistical software for Windows.

A P ≤0.05 was considered significant unless otherwise stated. The study was approved by the Ethics Committee for Medical Research in the county of Copenhagen.
TABLE 2. Clinical, Lifestyle, and Other Characteristics in Men on Medical Treatment for High BP Compared to Others

<table>
<thead>
<tr>
<th>Variables</th>
<th>On Medication, n=347</th>
<th>Others, n=2571</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipids, mmol/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>6.47 (1.14)</td>
<td>6.49 (1.10)</td>
<td>NS</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>4.29 (1.07)</td>
<td>4.42 (1.03)</td>
<td>0.04</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>1.28 (0.35)</td>
<td>1.37 (0.35)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>1.93 (1.13)</td>
<td>1.49 (1.01)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Combined high TG/low HDL-C</td>
<td>35.0%</td>
<td>18.0%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lifestyle factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol use, beverages/wk</td>
<td>19.8 (16.4)</td>
<td>17.6 (13.8)</td>
<td>0.006</td>
</tr>
<tr>
<td>Smoking</td>
<td>41%</td>
<td>57%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Physical activity, &lt;4 h/wk</td>
<td>55%</td>
<td>46%</td>
<td>0.001</td>
</tr>
<tr>
<td>Clinical/paraclinical factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>27.8 (4.2)</td>
<td>25.4 (3.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>133 (17)</td>
<td>119 (16)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>81 (12)</td>
<td>71 (11)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>NIDDM</td>
<td>4%</td>
<td>2%</td>
<td>0.003</td>
</tr>
<tr>
<td>Other characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low social class</td>
<td>52%</td>
<td>50%</td>
<td>NS</td>
</tr>
<tr>
<td>Age, y</td>
<td>63.6 (5.2)</td>
<td>62.7 (5.1)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Values are mean (SD) or frequencies in percent. P values of Student’s t test or χ² test for heterogeneity. Combined high TG/low HDL-C, triglycerides >1.59 mmol/L and HDL cholesterol <1.18 mmol/L.

combination with β-blockers, and 12.5% used diuretics in combination with other drugs; 22.5% used β-blockers as the only antihypertensive medication; ~4% used β-blockers in combination with other nondiuretics drugs; and the remaining 6% used other forms of antihypertensive medication including calcium channel blockers. There were no statistically significant differences in the number of drugs or the groups of drugs used between subjects with high TG/low HDL cholesterol and others.

Lipid and nonlipid IHD risk factor characteristics according to level of SBP in men taking no antihypertensive drugs are summarized in Table 1. Men with higher SBPs tended to have slightly higher total cholesterol and TG levels and a higher frequency of high TG/low HDL cholesterol. They also had a higher intake of alcohol, but fewer of them were smokers. They tended to have a higher BMI, a higher DBP, and they were older.

Table 2 summarizes differences in lipid and nonlipid IHD risk factor characteristics between men taking antihypertensive medication and the rest of the study population. Drug-treated men had significantly lower levels of LDL and HDL cholesterol and substantially higher levels of TG and a substantially higher frequency of high TG/low HDL cholesterol. They also had a higher intake of alcohol, they were less physically active, and fewer of them were smokers. They had a higher BMI, a higher SBP and DBP, more of them had a diagnosis of NIDDM, and they were older.

During the 8-year follow-up period, 229 men had a first IHD event, approximately one quarter of these events was fatal. In total, 426 men died from all causes. Table 3 shows the absolute and relative risk of IHD according to levels of SBP and presence of high TG/low HDL cholesterol in the entire study population. Overall, in subjects with high TG/low HDL cholesterol, the absolute and relative risks of IHD were independent of the level of SBP. In the rest of the study population, there was a steady increase in risk of IHD with increasing SBP that remained significant after adjustment for the other major risk factors of IHD. Excluding men (n=312) with ECG signs of left ventricular hypertrophy (LVH), strain, and silent ischemia, high-amplitude R, ST-depression, and T-wave abnormalities did not change the results presented in Table 3.

Table 4 shows the absolute risk of IHD according to SBP and presence of high TG/low HDL cholesterol in untreated men and in men taking antihypertensive medication, respectively. As a group, men taking antihypertensive medication had a significantly higher absolute risk of IHD compared with others: 12.1% (42/347) versus 7.4% (187/2532), P<0.01. In untreated men, the results basically corresponded to the results from the entire study population. In drug-treated men with high TG/low HDL cholesterol dyslipidemia, the absolute risk of IHD was independent of the level of SBP. In drug-treated men without high TG/low HDL cholesterol, the absolute risk of IHD tended to increase with increasing SBP.

Table 5 shows the absolute and relative risk of IHD according to levels of DBP and presence of high TG/low HDL cholesterol in the entire study population. In subjects with high TG/low HDL cholesterol, the absolute and relative

TABLE 3. Crude Cumulative Incidence (%) and Relative Risk of IHD According to Levels of SBP and Presence of High TG/Low HDL-C Versus Others in the Entire Population

<table>
<thead>
<tr>
<th>SBP, mm Hg</th>
<th>High TG/Low HDL-C</th>
<th>Others</th>
<th>Adjusted Relative Risk*</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;120</td>
<td>12.5% (30/241)</td>
<td>5.2% (60/1162)</td>
<td>1†</td>
</tr>
<tr>
<td>120–140</td>
<td>12.9% (33/255)</td>
<td>8.0% (72/901)</td>
<td>1.1 (0.6–1.9)</td>
</tr>
<tr>
<td>&gt;140</td>
<td>10.0% (8/80)</td>
<td>9.7% (26/267)</td>
<td>0.9 (0.4–2.2)</td>
</tr>
</tbody>
</table>

P=NS (Trend test) (Trend test) (Trend test) (Trend test)

Measurements of high TG/low HDL-C were triglycerides >1.59 mmol/L and HDL cholesterol <1.18 mmol/L.

*Confounders included age, total cholesterol, BMI, alcohol consumption, smoking, physical activity, NIDDM, and social class.

†Reference group in each category. ‡P<0.05 compared to reference group.
risks of IHD were independent of the level of DBP, although the relationship tended to resemble a U curve. In the rest of the study population, there was an increase in risk of IHD with increasing DBP that remained borderline significant after adjustment for the other major risk factors of IHD. Excluding subjects with ECG signs of LVH, strain, and silent ischemia did not change the results presented in the overall section of Table 5.

Table 6 shows the absolute risk of IHD according to DBP and presence of high TG/low HDL cholesterol in untreated men and in men taking antihypertensive medication, respectively. In untreated men, the results basically corresponded to the results from the entire study population. In drug-treated men with high TG/low HDL cholesterol, the absolute risk of IHD was substantially higher with a DBP <75 mm Hg, and this relationship remained significant after adjustment of the other major risk factors of IHD. In drug-treated men without high TG/low HDL cholesterol, the absolute risk of IHD was independent of the level of DBP.

In the entire study population, in subjects with high TG/low HDL cholesterol, the absolute risk of IHD was similar whether they had SBP >140 mm Hg and DBP >90 mm Hg or SBP <120 mm Hg and DBP <75 mm Hg, 11.1% versus 13.8%, respectively. In subjects without this dyslipidemia, the corresponding figures were 8.9% versus 4.9%.

Finally, we looked at the relationship between the lipid data from 1985 to 1986 and the BP values obtained from 1970 to 1971 when the CMS was initiated. Again, in men with high TG/low HDL cholesterol, the risk of IHD was not directly related to the level of SBP, whereas that was clearly the case in the rest of the study population (data not shown). With respect to DBP, men with high TG/low HDL cholesterol had a slightly higher risk of IHD with increasing DBP, but the relative increase in risk with increasing DBP from <80 to >90 mm Hg was ~25% of the increase seen in men without high TG/low HDL cholesterol (data not shown).

Discussion

Main Results

The major new finding in our study of middle-aged and elderly white men who were free of overt cardiovascular diseases at baseline was that the risk of IHD in subjects with high TG/low HDL cholesterol was not directly related to the level of SBP or DBP and that the previously described U-curved relationship between risk of IHD and level of treated DBP was only found in men with high TG/low HDL cholesterol. Because in BP-lowering trials investigators have not looked for special treatment effects in subgroups of hypertensive patients with and without this dyslipidemia, our findings may offer a possible explanation of the apparent paradox that lowering BP has not produced the expected reduction in risk of IHD in patients with hypertension.

Potential Bias and Study Limitations

Could our findings be the result of bias? In a previous paper we discussed the importance of validity of data and reporting bias. In the present cohort, well-known contributing factors to high BP such as age, alcohol use, physical inactivity, obesity, and a history of NIDDM were also highly correlated

---

**Table 5. Crude Cumulative Incidence (%) and Relative Risk of IHD According to Levels of DBP and Presence of High TG/Low HDL-C Versus Others in the Entire Population**

<table>
<thead>
<tr>
<th>DBP, mm Hg</th>
<th>High TG/low HDL-C</th>
<th>Others</th>
<th>Adjusted Relative Risk*</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;75</td>
<td>13.7% (37/270)</td>
<td>6.1% (86/1417)</td>
<td>1†</td>
</tr>
<tr>
<td>75–90</td>
<td>10.6% (27/255)</td>
<td>7.5% (58/771)</td>
<td>0.8 (0.5–1.5)</td>
</tr>
<tr>
<td>&gt;90</td>
<td>13.7% (7/51)</td>
<td>9.9% (14/142)</td>
<td>1.1 (0.4–2.9)</td>
</tr>
<tr>
<td></td>
<td>(Trend test)</td>
<td>(Trend test)</td>
<td>(Trend test)</td>
</tr>
</tbody>
</table>

*Confounders included age, total cholesterol, BMI, alcohol consumption, smoking, physical activity, NIDDM, and social class.
†Reference group in each category.
‡P<0.05 compared to reference group.
with the level of BP and a diagnosis of hypertension.\textsuperscript{28,29} Thus our study population does not appear to be unusual, and the overall reporting appears to be precise. In Denmark, diagnoses from official national registers are known to have a high validity,\textsuperscript{21–25} and it seems unlikely that men with high TG/low HDL cholesterol would be treated differently than others with respect to a diagnosis of IHD in the present study. Because we had reasonably similar results whether we used BP measurements from 1970 to 1971 or from 1985 to 1986, our findings do not appear to be the result of a selection bias. In our study, treated hypertensive subjects with high TG/low HDL cholesterol had the highest risk of IHD. Could it be possible that this observation was due to severe hypertension being treated with drugs that raise TG and lower HDL cholesterol? This does not appear to be the case. There were no statistically significant differences in the number of drugs or the groups of drugs being used between subjects with high TG/low HDL cholesterol and others, and in medical literature, raised TG levels that are associated with drug treatment do not seem to have any impact on risk of IHD.\textsuperscript{21–25}

At first sight, our results appear to be in contrast with the medical literature. Other cohort studies that have examined the relation of lipids and BP to the risk of IHD have generally found graded relationships between lipids, BP, and risk of IHD.\textsuperscript{29,31,32} However, none of these studies\textsuperscript{29,31,32} focused on the characteristic dyslipidemia seen in subjects with the metabolic syndrome X, high TG/low HDL cholesterol, a circumstance that may explain the discrepancy between their findings and our findings. On the other hand, a manuscript by Sheu et al\textsuperscript{33} provides substantial support for the notion that the increased risk of IHD in patients with hypertension is related to the metabolic syndrome X, with insulin resistance and its consequences. Sheu et al\textsuperscript{33} showed in a cross-sectional study design that patients with hypertension and evidence of IHD by ECG criteria were insulin resistant, hyperinsulinemic, and its consequences,45,46 and even a negative relation between both untreated and treated DBP has been reported in several studies.45,46 Such as the controversial J- or U-curved phenomenon.45,46 The J-curve is thought to be a consequence of

### TABLE 6. Crude Cumulative Incidence of IHD (%) According to Levels of DBP and Presence of High TG/Low HDL-C Versus Others According to Medical Treatment for High BP

<table>
<thead>
<tr>
<th>DBP, mm Hg</th>
<th>No Treatment</th>
<th>High TG/low HDL-C</th>
<th>Others</th>
<th>On Medication</th>
<th>High TG/low HDL-C</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;75</td>
<td>11.1% (27/243)</td>
<td>5.8% (79/1352)</td>
<td>37.0% (10/27)</td>
<td>10.8% (7/65)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75–90</td>
<td>11.0% (20/182)</td>
<td>7.3% (48/662)</td>
<td>9.6% (7/73)</td>
<td>9.2% (10/109)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;90</td>
<td>13.8% (4/29)</td>
<td>9.9% (9/91)</td>
<td>13.6% (3/22)</td>
<td>9.8% (5/51)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Measures of high TG/low HDL-C were triglycerides $>1.59$ mmol/L and HDL cholesterol $<1.18$ mmol/L.
underlying heart disease (eg, a fall in coronary flow reserve) and not the cause of IHD.45

On the basis of the observation described above, in high-risk subjects the risk of IHD is not necessarily directly related to the level of BP,45 thus we think our findings are biologically plausible. Because subjects with high TG/low HDL cholesterol have a series of athrogenic and thrombogenic changes, they have a high risk of IHD, and therefore they tend to resemble other high-risk populations. In addition, their risk of IHD will not be directly related to level of BP.

Clinical Implications

Our findings may have important clinical implications. Our results suggest that in hypertensive subjects with high TG/low HDL cholesterol, it may be more important to normalize high TG/low HDL cholesterol and the other components in the metabolic syndrome X to lower risk of IHD than to normalize BP. However, although lowering BP in some groups may have less than the expected effect on IHD, it should be pointed out that it is also still very important to lower BP in subjects with high TG/low HDL cholesterol to reduce the risk of stroke.2 In addition, the medical literature suggests that a multiple risk factor intervention strategy may be more important to lowering the risk of IHD in hypertensive patients than a strategy directed solely to the lowering of BP. In a prospective population-based observational study of 686 treated hypertensive men followed for 2 decades, the risk of IHD was still very high and the risk of IHD was not related to entry or in study BP but to lipid levels.47 In addition, post hoc subgroup analyses from randomized, placebo-controlled trials have suggested that lipid-lowering therapy may be useful in lowering the risk of IHD in subjects with hypertension.48,49

Acknowledgments

This study received grants from King Christian X’s Foundation, the Danish Medical Research Council, the Danish Heart Foundation, and Else & Mogens Wedell-Wedellsborg Foundation.

References

5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, E preferred link to a study or in study BP but to lipid levels.47 In addition, post hoc subgroup analyses from randomized, placebo-controlled trials have suggested that lipid-lowering therapy may be useful in lowering the risk of IHD in subjects with hypertension.48,49

Acknowledgments

This study received grants from King Christian X’s Foundation, the Danish Medical Research Council, the Danish Heart Foundation, and Else & Mogens Wedell-Wedellsborg Foundation.

References

32. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking,


High Triglycerides and Low HDL Cholesterol and Blood Pressure and Risk of Ischemic Heart Disease
Jørgen Jeppesen, Hans Ole Hein, Poul Suadicani and Finn Gyntelberg

doi: 10.1161/01.HYP.36.2.226
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/36/2/226

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/